Wellington Management Group LLP Takes $1.36 Million Position in Bruker Corporation $BRKR

Wellington Management Group LLP bought a new stake in shares of Bruker Corporation (NASDAQ:BRKR) in the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 22,683 shares of the medical research company’s stock, valued at approximately $1,365,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Public Employees Retirement System of Ohio acquired a new stake in shares of Bruker in the 2nd quarter worth about $1,999,000. Corient Private Wealth LP bought a new position in Bruker in the 2nd quarter worth about $233,000. Hsbc Holdings PLC bought a new position in Bruker in the 2nd quarter worth about $5,252,000. Expect Equity LLC acquired a new stake in shares of Bruker in the second quarter valued at approximately $4,269,000. Finally, Primecap Management Co. CA acquired a new stake in shares of Bruker in the second quarter valued at approximately $53,145,000. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Wolfe Research assumed coverage on Bruker in a research report on Monday, June 1st. They set a “peer perform” rating for the company. TD Cowen restated a “hold” rating on shares of Bruker in a research note on Wednesday, July 15th. Stifel Nicolaus set a $50.00 price objective on shares of Bruker in a report on Wednesday, August 5th. Guggenheim increased their target price on shares of Bruker from $50.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Bruker from $55.00 to $65.00 and gave the stock an “overweight” rating in a research report on Monday, June 8th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Bruker presently has an average rating of “Hold” and an average price target of $57.00.

Bruker Stock Down 0.2%

Shares of Bruker stock opened at $53.43 on Friday. Bruker Corporation has a 12-month low of $30.09 and a 12-month high of $65.30. The firm has a market capitalization of $8.14 billion, a PE ratio of -76.33, a price-to-earnings-growth ratio of 1.64 and a beta of 1.26. The company has a quick ratio of 0.92, a current ratio of 1.85 and a debt-to-equity ratio of 0.76. The stock’s fifty day moving average is $58.25 and its 200-day moving average is $49.25.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.11. The business had revenue of $838.50 million during the quarter, compared to analyst estimates of $853.57 million. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.Bruker’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the company posted $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Equities analysts anticipate that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Monday, September 21st will be issued a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, September 21st. Bruker’s dividend payout ratio (DPR) is presently -28.57%.

Bruker Company Profile

Bruker Corporation develops and manufactures scientific instruments, analytical systems and software used to study the chemical, physical and biological properties of materials. Its customers include universities, pharmaceutical and biotechnology companies, industrial manufacturers, hospitals, government laboratories and other research organizations.

The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, X-ray analysis instruments, optical and molecular spectroscopy systems, microscopy and nanoanalysis tools, and instruments for microbiology and spatial biology.